Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus

Objective. Hydroxychloroquine (HCQ) is a commonly used medicine for the treatment of systemic lupus erythematosus (SLE), and Th17 cells are closely related to the pathogenesis of SLE. However, the role and mechanism of HCQ on Th17 cell differentiation in SLE is not clearly understood. Here, we investigate the effect of HCQ on Th17 cell differentiation both in vitro and in patients with SLE. Methods. Twenty-five patients with SLE were divided into 2 treatment groups: prednisone alone and HCQ plus prednisone. Interleukin 17 (IL-17) expression was analyzed by ELISA and real-time (RT)-PCR. Th17 were measured in patients with SLE by flow cytometry before and after HCQ treatment. In vitro, naive T cells were cultured in Th17-inducing conditions with or without HCQ. Cell differentiation and IL-17 expression were analyzed. Finally, transcriptome sequencing identified differential gene expression between naive T cells and induced Th17 cells. Results. In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation. In vitro, HCQ inhibited Th17 cell proliferation and differentiation, as well as IL-17 production. Five microRNA were significantly different in Th17 cells compared with naive T cells, and HCQ treatment reversed this effect. In vivo, microRNA-590 (miR-590) was verified and was significantly decreased in Th17 cells, compared with naive T cells from lupus-prone mice. Moreover, miR-590 was increased in patients treated with HCQ plus prednisone. Conclusion. HCQ inhibited Th17 cell differentiation and IL-17 production both in vitro and in patients with SLE. Our study provides additional evidence for HCQ as a treatment for SLE.

[1]  Ruth Gamble.  Lineages , 2018, Oxford Scholarship Online.

[2]  G. Tsokos,et al.  T cells and IL-17 in lupus nephritis. , 2017, Clinical immunology.

[3]  Anthony P Fernandez.  Updated recommendations on the use of hydroxychloroquine in dermatologic practice , 2017, Journal of the American Academy of Dermatology.

[4]  L. Morel.  Immunometabolism in systemic lupus erythematosus , 2017, Nature Reviews Rheumatology.

[5]  Shan-Chi Liu,et al.  YKL-40-Induced Inhibition of miR-590-3p Promotes Interleukin-18 Expression and Angiogenesis of Endothelial Progenitor Cells , 2017, International journal of molecular sciences.

[6]  Y. Qiao,et al.  Leptin levels in patients with systemic lupus erythematosus inversely correlate with regulatory T cell frequency , 2017, Lupus.

[7]  C. Ponticelli,et al.  Hydroxychloroquine in systemic lupus erythematosus (SLE) , 2017, Expert opinion on drug safety.

[8]  G. Steiner,et al.  Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation , 2017, Scientific Reports.

[9]  K. Lackner,et al.  Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase , 2016, Annals of the rheumatic diseases.

[10]  F. Pan,et al.  Foxp3, Regulatory T Cell, and Autoimmune Diseases , 2016, Inflammation.

[11]  Ming Li,et al.  Oxidative Stress and Treg and Th17 Dysfunction in Systemic Lupus Erythematosus , 2016, Oxidative medicine and cellular longevity.

[12]  J. Harley,et al.  In Vivo Therapeutic Success of MicroRNA‐155 Antagomir in a Mouse Model of Lupus Alveolar Hemorrhage , 2016, Arthritis & rheumatology.

[13]  M. Dougados,et al.  Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. , 2015, The New England journal of medicine.

[14]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[15]  Andreas Radbruch,et al.  Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus , 2015, Annals of the rheumatic diseases.

[16]  Q. Lu,et al.  Interleukin-17 in systemic lupus erythematosus: A comprehensive review , 2015, Autoimmunity.

[17]  Yuehua Wu,et al.  miR-590-3p Is a Novel MicroRNA in Myocarditis by Targeting Nuclear Factor Kappa-B in vivo , 2015, Cardiology.

[18]  Zhaojian Liu,et al.  miR-155 Deficiency Ameliorates Autoimmune Inflammation of Systemic Lupus Erythematosus by Targeting S1pr1 in Faslpr/lpr Mice , 2015, The Journal of Immunology.

[19]  Qiao Li,et al.  Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice , 2015, Molecular medicine.

[20]  Ming Li,et al.  Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway , 2014, Arthritis Research & Therapy.

[21]  B. Hahn,et al.  Th17 cells in inflammation and autoimmunity. , 2014, Autoimmunity reviews.

[22]  Min Zhang,et al.  MicroRNA-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting lipoprotein lipase gene in human THP-1 macrophages. , 2014, Biochimie.

[23]  M. Genovese,et al.  Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. , 2014, The New England journal of medicine.

[24]  Ming Li,et al.  Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction , 2014, Arthritis Research & Therapy.

[25]  S. Monticelli.  MicroRNAs in T helper cell differentiation and plasticity. , 2013, Seminars in immunology.

[26]  K. Mark Ansel,et al.  MicroRNA-mediated regulation of T helper cell differentiation and plasticity , 2013, Nature Reviews Immunology.

[27]  S. Galdino,et al.  Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients , 2013, Clinics.

[28]  R. Spreafico,et al.  Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. , 2013, The Journal of allergy and clinical immunology.

[29]  C. Norbury,et al.  The Long and Short of MicroRNA , 2013, Cell.

[30]  Ming Li,et al.  Identification of Baicalin as an Immunoregulatory Compound by Controlling TH17 Cell Differentiation , 2011, PloS one.

[31]  V. Kuchroo,et al.  Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23–Th17 pathway , 2009, The Journal of experimental medicine.

[32]  Ming Li,et al.  Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[33]  W. Ouyang,et al.  Novel therapeutic targets along the Th17 pathway , 2009, European journal of immunology.

[34]  L. Garrett-Sinha,et al.  IL-17 and the Th17 lineage in systemic lupus erythematosus , 2008, Current opinion in rheumatology.

[35]  D. Ye,et al.  Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus , 2008, Nature Clinical Practice Rheumatology.

[36]  Robert W. Williams,et al.  Interleukin 17–producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice , 2008, Nature Immunology.

[37]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[38]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[39]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[40]  V. French,et al.  The long and the short of it , 1993, Nature.

[41]  Dai Li,et al.  miR-590-3p mediates the protective effect of curcumin on injured endothelial cells induced by angiotensin II. , 2017, American journal of translational research.

[42]  C. Joseph.  Plasticity. , 2013, Handbook of clinical neurology.

[43]  Supporting Online Material , 2002 .

[44]  T. Takahashi.  [Erythematosus]. , 1971, Nihon rinsho. Japanese journal of clinical medicine.

[45]  Nephritis. , 1938, California and western medicine.